Your browser is no longer supported. Please, upgrade your browser.
Settings
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own3.70% Shs Outstand122.44M Perf Week-5.96%
Market Cap752.10M Forward P/E- EPS next Y-0.45 Insider Trans396.56% Shs Float55.40M Perf Month-23.37%
Income-58.60M PEG- EPS next Q-0.16 Inst Own85.40% Short Float6.74% Perf Quarter-37.27%
Sales24.00M P/S31.34 EPS this Y-147.40% Inst Trans15.96% Short Ratio2.00 Perf Half Y248.28%
Book/sh1.28 P/B3.95 EPS next Y-18.40% ROA-21.80% Target Price- Perf Year152.50%
Cash/sh1.02 P/C4.94 EPS next 5Y- ROE-81.30% 52W Range1.03 - 9.65 Perf YTD47.66%
Dividend- P/FCF- EPS past 5Y-63.50% ROI-27.90% 52W High-48.81% Beta1.50
Dividend %- Quick Ratio3.40 Sales past 5Y-28.70% Gross Margin92.00% 52W Low379.61% ATR0.32
Employees78 Current Ratio3.40 Sales Q/Q-97.70% Oper. Margin- RSI (14)27.93 Volatility5.84% 5.48%
OptionableYes Debt/Eq0.07 EPS Q/Q90.70% Profit Margin- Rel Volume0.35 Prev Close5.05
ShortableYes LT Debt/Eq0.00 EarningsMar 10 AMC Payout- Avg Volume1.87M Price4.94
Recom2.70 SMA20-13.23% SMA50-26.92% SMA20037.67% Volume456,036 Change-2.18%
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Apr-19-21 12:30PM  
Apr-08-21 04:35PM  
Mar-15-21 08:36AM  
Mar-10-21 05:55PM  
04:10PM  
02:15PM  
Mar-04-21 04:05PM  
12:30PM  
Mar-03-21 12:40PM  
Mar-02-21 10:02AM  
Mar-01-21 10:33AM  
Feb-26-21 10:13AM  
Feb-11-21 11:05AM  
Feb-06-21 06:55AM  
Jan-31-21 02:55AM  
Jan-29-21 06:56AM  
Jan-22-21 10:18AM  
Jan-20-21 12:13PM  
Jan-15-21 08:31AM  
Jan-14-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 09:40AM  
Dec-31-20 08:00AM  
06:11AM  
Dec-16-20 04:05PM  
Dec-12-20 04:03PM  
Dec-11-20 06:04PM  
08:02AM  
07:38AM  
Dec-09-20 09:22AM  
Nov-16-20 10:02PM  
08:00AM  
Nov-06-20 07:48AM  
Oct-29-20 10:05AM  
08:02AM  
06:00AM  
06:00AM  
Oct-27-20 08:00AM  
Sep-23-20 06:43PM  
Sep-14-20 09:46AM  
Sep-08-20 04:05PM  
Sep-04-20 08:00AM  
Sep-03-20 06:00PM  
Aug-24-20 11:35AM  
Aug-10-20 11:52AM  
Aug-03-20 07:25AM  
Aug-02-20 09:54AM  
Jul-30-20 06:00PM  
03:52PM  
10:55AM  
07:15AM  
07:10AM  
07:00AM  
Jul-23-20 07:00AM  
Jul-22-20 12:32PM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jul-14-20 01:19PM  
Jul-04-20 02:02PM  
Jun-13-20 11:01AM  
Jun-11-20 05:22PM  
May-27-20 07:00AM  
May-13-20 05:30PM  
Apr-27-20 06:33PM  
04:24PM  
08:15AM  
07:43AM  
07:00AM  
Apr-22-20 05:41PM  
Apr-20-20 10:04AM  
Apr-07-20 07:00AM  
Mar-30-20 11:11AM  
Mar-20-20 07:44AM  
Mar-19-20 04:01PM  
Mar-13-20 08:05AM  
Mar-12-20 01:40PM  
09:35AM  
07:00AM  
Mar-05-20 07:00AM  
Mar-04-20 12:30PM  
Jan-24-20 03:00PM  
Jan-20-20 04:01PM  
08:07AM  
Jan-09-20 02:50PM  
Jan-06-20 06:09PM  
Dec-20-19 08:31AM  
07:00AM  
Dec-19-19 08:28PM  
Dec-13-19 08:52AM  
Dec-05-19 12:54PM  
07:00AM  
Dec-03-19 07:00AM  
Dec-02-19 11:09AM  
09:57AM  
07:58AM  
07:00AM  
Nov-26-19 04:01PM  
Nov-15-19 11:17PM  
Nov-14-19 08:09PM  
09:10AM  
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tessmer James FVP, Finance & AccountingMar 15Option Exercise3.3112,00039,72083,766Mar 16 07:45 PM
Tessmer James FVP, Finance & AccountingMar 15Sale6.9222,912158,44071,766Mar 16 07:45 PM
Artal International S.C.A.DirectorDec 16Buy3.2010,937,50035,000,00032,259,461Dec 17 02:43 PM
Invus Public Equities, L.P.DirectorDec 16Buy3.2010,937,50035,000,00032,259,461Dec 17 02:39 PM
SOBECKI CHRISTOPHER JDirectorApr 26Option Exercise0.003,4660140,759Apr 27 04:48 PM
Swain Judith LDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:49 PM
Palantoni FrankDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:48 PM
NIES ALAN SDirectorApr 26Option Exercise0.003,466017,082Apr 27 04:47 PM
DEBBANE RAYMONDDirectorApr 26Option Exercise0.003,4660316,883Apr 27 04:45 PM
LEFKOWITZ ROBERT J MDDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:46 PM
BARKER SAM LDirectorApr 26Option Exercise0.003,466055,653Apr 27 04:44 PM
Amouyal PhilippeDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:43 PM